The ALUNBRIG SMART™ Free
Trial Program

Is ALUNBRIG® (brigatinib) right for you?
The ALUNBRIG SMART Program can help you and your doctor decide. If eligible, you will receive a 1-month trial at no cost, shipped directly to you. Talk with your doctor to see if the program might be right for you.

  • Eligible patients must have an ICD-10 code verifying the diagnosis of ALK+ metastatic NSCLC, be a new patient not currently using ALUNBRIG, and not have been previously enrolled in the ALUNBRIG SMART Program. Additional terms apply
  • This free trial offer is solely intended to allow new patients to try ALUNBRIG and to determine with their healthcare provider whether ALUNBRIG is right for them. There is no obligation for you to continue use of ALUNBRIG after the free trial has been completed. ALUNBRIG SMART is not meant to induce or require future/continuing prescriptions of ALUNBRIG
ICD-10, International Classifications of Disease, Tenth Revision.

ALUNBRIG(TM) BRIGATINIB 39 mg TABLETS

This site is intended for residents
of the US and US territories only.

ALUNBRIG® (brigatinib)—NOW
APPROVED
For Adults With
NEWLY DIAGNOSED
ALK+ Metastatic NSCLC

Click on the buttons below for more information about this new indication, or continue on to learn more about using ALUNBRIG as an option after crizotinib. Check back soon for more first-line information.



Please read Important Safety Information below.

05/20 USO-BRG-0109

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib) and entering one that is not owned or controlled by Takeda Oncology.

Takeda Oncology makes no representation as to the accuracy of the information contained on sites we do not own or control. Takeda Oncology does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Cancel Continue >
Close

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib) and entering one that is not owned or controlled by Takeda Oncology.

This link will take you to the corporate ARIAD Pharmaceuticals, Inc. website.

Cancel Continue >
Close

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib).

This link will take you to another Takeda Oncology website.

Cancel Continue >
Close

The site you are about to enter is intended for US healthcare professionals only.

Please confirm that you are a US healthcare professional.

Yes, I confirm that I am a US healthcare professional Cancel
Close

In Vitro: ALUNBRIG Inhibited 17
ALK-Inhibitor-Resistant Mutations1,2

ALUNBRIG exhibited in vivo antitumor activity against 4 mutant forms of EML4-ALK, including the G1202R and L1196M mutants identified in NSCLC tumors in patients who had progressed on crizotinib.

 

We use cookies to gather web statistics that help us improve our site. We store no personal details.
ACCEPT

Read More